Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Fast Forward LLC Stories

2013-12-17 08:30:27

-- The National MS Society through Fast Forward and EMD Serono provide funding of up to $1.3 million in 2013 to accelerate early-stage research in MS -- NEW YORK and ROCKLAND, Mass., Dec. 17, 2013 /PRNewswire-USNewswire/ -- The National Multiple Sclerosis Society through Fast Forward and EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the fourth group of recipients to receive funding through their collaboration, which is designed to accelerate innovation...

2013-12-17 08:30:13

- EMD Serono and the National MS Society through Fast Forward provide funding of up to $1.3 million in 2013 to accelerate early-stage research in MS ROCKLAND, Mass. and NEW YORK, Dec. 17, 2013 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and the National Multiple Sclerosis Society through Fast Forward today announced the fourth group of recipients to receive funding through their collaboration, which is designed to accelerate innovation and commercial...

2013-10-01 08:31:54

NEW YORK, Oct. 1, 2013 /PRNewswire-USNewswire/ -- The National Multiple Sclerosis Society today announced that it has entered into a research collaboration agreement with GE Healthcare through Fast Forward, a not for profit subsidiary of the National Multiple Sclerosis Society, to co-fund a clinical study with the GE investigational PET tracer, GE180, in patients with multiple sclerosis (MS). The clinical study, which will be enrolling patients in the United Kingdom, is aimed to aid...

2013-09-27 08:26:09

-- Awards advance Society's NOW Campaign goals to protect and restore nerve-insulating myelin damaged by multiple sclerosis and bring about recovery of function for people living with the disease NEW YORK, Sept. 27, 2013 /PRNewswire-USNewswire/ -- The National Multiple Sclerosis Society has just committed $7 million to support 15 new research projects focusing on innovative approaches to repair the coating of myelin that protects nerve fibers and which is destroyed by the MS disease process....

2013-04-09 12:29:09

BROOMFIELD, Colo., April 9, 2013 /PRNewswire/ -- Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative clinical applications to address acute and chronic neurodegenerative diseases, announced today a study in collaboration with the University of Miami Miller School of Medicine. The study will examine the effects of Accera's medical food, Axona, on cognitive impairment in patients with multiple sclerosis (MS). Axona is a...

2012-12-20 08:27:04

ROCKLAND, Mass. and NEW YORK, Dec. 20, 2012 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and Fast Forward LLC, a wholly-owned subsidiary of the National Multiple Sclerosis Society, today announced the third group of recipients to receive funding through their collaboration, which is designed to accelerate innovation and commercial development of multiple sclerosis (MS) therapies. (Logo: http://photos.prnewswire.com/prnh/20121220/SF32295LOGO-a) (Logo:...

2012-11-08 08:34:49

GAITHERSBURG, Md., Nov. 8, 2012 /PRNewswire/ -- DioGenix, Inc. today announced an alliance with Fast Forward, a subsidiary of the National Multiple Sclerosis Society, to develop a novel blood test for multiple sclerosis (MS). Fast Forward will provide up to $500,000 as part of a Sponsored Research Agreement that will enable DioGenix to expand an ongoing clinical trial of its MS diagnostic, MSPrecise(TM), a proprietary next-generation sequencing assay that measures changes to the adaptive...

2011-12-14 06:30:00

SALT LAKE CITY, Dec. 14, 2011 /PRNewswire/ -- Lineagen, Inc., an innovative molecular diagnostics company focused on complex, genetically linked disorders, and Fast Forward, LLC, a nonprofit subsidiary of the National Multiple Sclerosis Society, today announced an alliance to fund the clinical development and validation of a blood-based assay for multiple sclerosis (MS). The goal of the program is to develop a test that can aid clinicians in diagnosing MS, distinguishing it from...

2010-11-17 09:00:00

NEW YORK and NORTH BRUNSWICK, N.J., Nov. 17, 2010 /PRNewswire/ -- Provid Pharmaceuticals, Inc, a drug discovery company, and Fast Forward, LLC, the National Multiple Sclerosis Society's subsidiary devoted to bridging the gap between research and drug development, today announced an expansion of their partnership to support Provid's preclinical studies of their candidate MS drug, PV-267. This novel, highly selective small molecule is designed to block a critical step in the autoimmune...

2010-01-19 08:00:00

Patient Advocacy Partners Forge Collaboration to Fund Discovery of New Drugs that Target the Immune System NEW YORK and MILAN, Italy, Jan. 19 /PRNewswire-USNewswire/ -- Fast Forward, LLC, the commercial drug development arm of the National Multiple Sclerosis Society, and the Juvenile Diabetes Research Foundation (JDRF), the leader in research leading to a cure for type 1 diabetes in the world today announced a collaborative partnership with Axxam SpA -- a leading company in conducting...